Chemical Property of Epalrestat
Chemical Property:
- Appearance/Colour:Deep red acicular crystal
- Vapor Pressure:1.66E-11mmHg at 25°C
- Melting Point:210-217 °C
- Refractive Index:1.705
- Boiling Point:516.8 °C at 760 mmHg
- PKA:3.62±0.10(Predicted)
- Flash Point:266.4 °C
- PSA：115.00000
- Density:1.43 g/cm3
- LogP:2.85660
- Storage Temp.:-20°C Freezer
- Solubility.:DMSO: soluble5mg/mL, clear (warmed)
- XLogP3:3.8
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:5
- Rotatable Bond Count:4
- Exact Mass:319.03368562
- Heavy Atom Count:21
- Complexity:519
- Purity/Quality:
-
99.2% *data from raw suppliers
Epalrestat *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CC(=CC1=CC=CC=C1)C=C2C(=O)N(C(=S)S2)CC(=O)O
- Isomeric SMILES:C/C(=C\C1=CC=CC=C1)/C=C\2/C(=O)N(C(=S)S2)CC(=O)O
- Recent ClinicalTrials:Research of SORD-CMT Natural History and Epalrestat Treatment
- Recent NIPH Clinical Trials:Epalrestat effect on diabetic neuropathy in primary care setting
-
Description
Epalrestat is the second aldose reductase inhibitor to be introduced worldwide and the
first to be launched in Japan. The compound is indicated for the treatment of diabetic
neuropathy. It is also being investigated for diabetic retinopathy and nephropathy.
-
Uses
Epalrestat has been used as an aldose reductase inhibitor: in the dahomey larvae diet fed forDrosophilafor non-irradiated and X-ray irradiated human aldose reductaseto test its protective effect in mice with bleomycin-induced pulmonary fibrosis Epalrestat is an aldose reductase inhibitor with IC50 of 72 nM An aldose reductase inhibitor. It is used in treatment of diabetic neuropathy.
